Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in ...

The FDA approved inavolisib for triplet combination use for treatment of PIK3CA-mutated locally advanced or metastatic ...

The following is a summary of “Outcomes of De Novo Oligometastatic Breast Cancer Treated With Surgery of Primary and ...

The objective response rate was 78.6% in the overall cohort, 76.9% in patients with a PD-L1 combined positive score (CPS) below 1, 68.8% in patients with a PD-L1 CPS of 1-9, and 100% in patients with ...

The human immune system is a complex network of cells and signals that guards against disease, yet in the case of cancer, it ...

Mark A. Lewis, MD, discussed the promise of the ESOPEC and TRANSMET trials and the need for their further investigation.

Now, China-based CARsgen has shared pivotal results from the latter portion of a phase 1/2 study evaluating the therapy for ...

J&J has reported positive topline outcomes from the MARIPOSA trial of RYBREVANT and LAZCLUZE combo for NSCLC treatment.

Veliparib plus temozolomide did not significantly extend overall survival in patients with newly diagnosed, ...

Shares of Verastem Oncology (VSTM) are up over 40% at $5.17 in premarket trading Tuesday, following a regulatory update. The ...

A retrospective chart review compared the difference in outcomes between Black patients and White patients with advanced RCC for 3 first-line therapies.